Evaluating societal preferences for human papillomavirus vaccine and cervical smear test screening programme
暂无分享,去创建一个
David Patrick | Carlo A Marra | Larry D Lynd | L. Lynd | C. Marra | F. Marra | G. Ogilvie | D. Patrick | Bridgette Oteng | Fawziah Marra | Gina Ogilvie | Bridgette Oteng
[1] C. Maxwell,et al. Factors Important in Promoting Cervical Cancer Screening among Canadian Women: Findings from the 1996–97 National Population Health Survey (NPHS) , 2001, Canadian journal of public health = Revue canadienne de sante publique.
[2] C. Marra,et al. Effectiveness and Cost Effectiveness of Human Papillomavirus Vaccine , 2012, PharmacoEconomics.
[3] M. Naus,et al. Parental intention to have daughters receive the human papillomavirus vaccine , 2007, Canadian Medical Association Journal.
[4] F. Olesen. A case-control study of cervical cytology before diagnosis of cervical cancer in Denmark. , 1988, International journal of epidemiology.
[5] A Ludbrook,et al. Use of discrete choice experiments to elicit preferences , 2001, Quality in health care : QHC.
[6] Daron G Ferris,et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. , 2007, The New England journal of medicine.
[7] David R. Scott,et al. Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis. , 2003, Journal of the National Cancer Institute.
[8] F. X. Bosch,et al. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions , 2007 .
[9] D. Eddy. Screening for cervical cancer. , 1990, Annals of internal medicine.
[10] C. Wheeler,et al. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials , 2007, The Lancet.
[11] N. Kiviat,et al. Development and duration of human papillomavirus lesions, after initial infection. , 2005, The Journal of infectious diseases.
[12] A. Miller. Failures of cervical cancer screening. , 1995, American journal of public health.
[13] Rosalie Viney,et al. Using stated preference discrete choice modelling to evaluate the introduction of varicella vaccination. , 2002, Health economics.
[14] K. Aronson,et al. Oncogenic Human Papillomavirus Infection and Cervical Lesions in Aboriginal Women of Nunavut, Canada , 2001, Sexually transmitted diseases.
[15] S. Goldie,et al. The value of including boys in an HPV vaccination programme: a cost-effectiveness analysis in a low-resource setting , 2007, British Journal of Cancer.
[16] W. Edmunds,et al. Cost-effectiveness analyses of human papillomavirus vaccination. , 2007, The Lancet. Infectious diseases.
[17] Edson Duarte Moreira Júnior,et al. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. , 2007, The New England journal of medicine.
[18] Erik J. Dasbach,et al. Model for Assessing Human Papillomavirus Vaccination Strategies , 2007, Emerging infectious diseases.
[19] Henry C Kitchener,et al. Future acceptance of adolescent human papillomavirus vaccination: a survey of parental attitudes. , 2006, Vaccine.
[20] P. Garcia,et al. Examination of volunteer bias in research involving patients diagnosed with psychogenic nonepileptic seizures , 2009, Epilepsy & Behavior.
[21] L Beardsley,et al. Natural history of cervicovaginal papillomavirus infection in young women. , 1998, The New England journal of medicine.
[22] C. Carswell. Measuring and Valuing Health Benefits for Economic Valuation , 2007, PharmacoEconomics.
[23] A Ludbrook,et al. Use of discrete choice experiments to elicit preferences , 2001 .
[24] J. Peto,et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide , 1999, The Journal of pathology.
[25] John M. Rose,et al. Applied Choice Analysis: A Primer , 2005 .
[26] T. Hofer,et al. Socioeconomic disparities in preventive care persist despite universal coverage. Breast and cervical cancer screening in Ontario and the United States. , 1994, JAMA.
[27] C Milligan,et al. Screening for cervical cancer. , 1975, The American journal of nursing.
[28] J. Fortenberry,et al. A longitudinal study of genital human papillomavirus infection in a cohort of closely followed adolescent women. , 2005, The Journal of infectious diseases.
[29] Julie Ratcliffe,et al. Measuring and valuing health benefits for economic evaluation in adolescence: an assessment of the practicality and validity of the child health utility 9D in the Australian adolescent population. , 2012, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[30] W. Melchers,et al. Parental acceptance of Human Papillomavirus vaccines. , 2008, European journal of obstetrics, gynecology, and reproductive biology.
[31] Howard Bauchner,et al. Parental acceptance of the human papillomavirus vaccine. , 2005, The Journal of adolescent health : official publication of the Society for Adolescent Medicine.
[32] L. Lynd,et al. An Evaluation of Patients' Willingness to Trade Symptom-Free Days for Asthma-Related Treatment Risks: A Discrete Choice Experiment , 2008, The Journal of asthma : official journal of the Association for the Care of Asthma.
[33] C. Quach,et al. National Advisory Committee on Immunization (NACI). , 1989, Canada diseases weekly report = Rapport hebdomadaire des maladies au Canada.